We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.84%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.05B
AUM Growth
+$146M
Cap. Flow
-$430M
Cap. Flow %
-8.52%
Top 10 Hldgs %
43.4%
Holding
134
New
26
Increased
24
Reduced
35
Closed
22

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$129M
2
MRK icon
Merck
MRK
+$76.6M
3
GH icon
Guardant Health
GH
+$43.7M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$31.5M
5
QURE icon
uniQure
QURE
+$28.3M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$87M
2
LLY icon
Eli Lilly
LLY
+$65.3M
3
APLS
Apellis Pharmaceuticals
APLS
+$61M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.8M
5
CI icon
Cigna
CI
+$56.4M

Sector Composition

Rank Sector Weight
1 Healthcare 90.42%
2 Miscellaneous 9.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
101
PTC Therapeutics
PTCT
$5.85B
$3.35M 0.07%
49,100
+25,900
+112% +$1.83M
LFST icon
102
Lifestance Health
LFST
$4.75B
$3.19M 0.06%
+500,000
New +$3.48M
DRUG
103
Bright Minds Biosciences
DRUG
$716M
$2.92M 0.06%
+40,000
New +$3.22M
JBIO
104
Jade Biosciences
JBIO
$1.33B
$2.6M 0.05%
185,011
-346,152
-65% -$5.01M
CCCC icon
105
C4 Therapeutics
CCCC
$477M
$2.25M 0.04%
856,353
-548,549
-39% -$1.29M
KALV
106
DELISTED
KalVista Pharmaceuticals
KALV
$1.9M 0.04%
94,400
-288,000
-75% -$4.64M
IMA
107
ImageneBio Inc
IMA
$60.6M
$1.89M 0.04%
378,556
– –
VTGN icon
108
VistaGen Therapeutics
VTGN
$11.2M
$1.75M 0.03%
3,060,000
– –
ATAI icon
109
AtaiBeckley Inc
ATAI
$2.73B
$1.23M 0.02%
+347,000
New +$1.31M
TRAW icon
110
Traws Pharma
TRAW
$9.13M
$1.11M 0.02%
605,531
– –
APLS
111
DELISTED
Apellis Pharmaceuticals
APLS
– –
-2,429,868
Closed -$61M
BRKR icon
112
Bruker
BRKR
$8.74B
– –
-555,789
Closed -$26.2M
CELC icon
113
Celcuity
CELC
$4.33B
– –
-85,664
Closed -$8.54M
CI icon
114
Cigna
CI
$73.6B
– –
-205,000
Closed -$56.4M
CTMX icon
115
CytomX Therapeutics
CTMX
$717M
– –
-3,525,650
Closed -$15M
EW icon
116
CALL
Edwards Lifesciences
EW
$52B
– –
-150,000
Closed -$12.8M
EXAS
117
DELISTED
Exact Sciences
EXAS
– –
-351,716
Closed -$35.7M
FOLD
118
DELISTED
Amicus Therapeutics
FOLD
– –
-729,900
Closed -$10.4M
INSM icon
119
Insmed
INSM
$25.9B
– –
-25,400
Closed -$4.42M
NBIX icon
120
Neurocrine Biosciences
NBIX
$15.6B
– –
-314,240
Closed -$44.6M
OCUL icon
121
Ocular Therapeutix
OCUL
$2.29B
– –
-157,300
Closed -$1.91M
PMVP icon
122
PMV Pharmaceuticals
PMVP
$65.2M
– –
-4,975,291
Closed -$6.22M
RAPT
123
DELISTED
RAPT Therapeutics
RAPT
– –
-1,642,891
Closed -$55.6M
RNAM
124
DELISTED
Avidity Biosciences
RNAM
– –
-619,530
Closed -$44.7M
ROIV icon
125
Roivant Sciences
ROIV
$25.7B
– –
-2,190,907
Closed -$47.5M
2 3 4
5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2026 Portfolio in Review

As of Q1 2026, OrbiMed held 134 positions worth $5.05B, up 3% from $4.9B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

OrbiMed withdrew a net $430M in Q1 2026, closing 22 positions and reducing 35 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in AstraZeneca worth $132M.

  • OrbiMed's largest Q1 2026 buy was AstraZeneca: 670,200 shares worth $132M.
  • OrbiMed added most to Mineralys Therapeutics in Q1 2026, an estimated $31.5M increase.
  • OrbiMed's biggest Q1 2026 reduction was Eli Lilly, cutting an estimated $65.3M.
  • OrbiMed fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 43% of its $5.05B portfolio in Q1 2026.
  • OrbiMed opened 26 new positions and closed 22 in Q1 2026.
  • OrbiMed's portfolio value rose 3% quarter-over-quarter to $5.05B.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.